Literature DB >> 17195098

Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol: a meta-analysis.

João Batista A Oliveira1, Ana Lucia Mauri, Claudia G Petersen, Anice M C Martins, João Cornicelli, Mario Cavanha, Anagloria Pontes, Ricardo L R Baruffi, José G Franco.   

Abstract

PURPOSE: to compare the efficacy of recombinant LH supplementation for controlled ovarian stimulation in recombinant FSH and GnRH-agonist protocol.
METHODS: Search strategies included on-line surveys of databases. The fixed effects model was used for odds ratio and effect size (weighted mean difference). Four trials fulfilled the inclusion criteria.
RESULTS: a fewer days of stimulation (p<0.0001), a fewer total amount of r-FSH administered (p<0.0001) and a higher serum estradiol levels on the day of hCG administration (p<0.0001) were observed for the r-LH supplementation protocol. However, differences were not observed in number of oocyte retrieved, number of mature oocytes, clinical pregnancy per oocyte retrieval, implantation and miscarriage rates.
CONCLUSIONS: more randomized controlled trials are necessary before evidence-based recommendations regarding exogenous LH supplementation in ovarian stimulation protocols with FSH and GnRH-agonist for assisted reproduction treatment can be provided.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17195098      PMCID: PMC3454989          DOI: 10.1007/s10815-006-9095-4

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  23 in total

Review 1.  Multiple novel roles of luteinizing hormone.

Authors:  C V Rao
Journal:  Fertil Steril       Date:  2001-12       Impact factor: 7.329

Review 2.  Gonadotropic control of ovarian follicular growth and development.

Authors:  S G Hillier
Journal:  Mol Cell Endocrinol       Date:  2001-06-20       Impact factor: 4.102

Review 3.  Follicle selection in primates: "many are called but few are chosen".

Authors:  A J Zeleznik
Journal:  Biol Reprod       Date:  2001-09       Impact factor: 4.285

4.  Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence.

Authors:  Jan Tesarik; Carmen Mendoza
Journal:  Hum Reprod       Date:  2002-12       Impact factor: 6.918

5.  Use of recombinant LH in a group of unselected IVF patients.

Authors:  F Lisi; L Rinaldi; S Fishel; R Lisi; G P Pepe; M G Picconeri; A Campbell
Journal:  Reprod Biomed Online       Date:  2002 Sep-Oct       Impact factor: 3.828

Review 6.  Actions of gonadotrophins on the uterus.

Authors:  M Shemesh
Journal:  Reproduction       Date:  2001-06       Impact factor: 3.906

7.  Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH.

Authors:  G De Placido; A Mollo; C Alviggi; I Strina; M T Varricchio; A Ranieri; N Colacurci; A Tolino; M Wilding
Journal:  Hum Reprod       Date:  2001-09       Impact factor: 6.918

8.  Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction.

Authors:  L G Westergaard; S B Laursen; C Y Andersen
Journal:  Hum Reprod       Date:  2000-05       Impact factor: 6.918

Review 9.  LH in the follicular phase: neither too high nor too low.

Authors:  Juan Balasch; Francisco Fábregues
Journal:  Reprod Biomed Online       Date:  2006-04       Impact factor: 3.828

Review 10.  The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation.

Authors:  Zeev Shoham
Journal:  Fertil Steril       Date:  2002-06       Impact factor: 7.329

View more
  9 in total

1.  The effect of rLH supplementation to the GnRH-antagonist protocol on endocrine dynamics in the advanced reproductive age.

Authors:  J S Younis; I Izhaki; M Ben-Ami
Journal:  J Endocrinol Invest       Date:  2017-03-13       Impact factor: 4.256

2.  Recombinant follitropin alfa/lutropin alfa in fertility treatment.

Authors:  Ahmed Gibreel; Siladitya Bhattacharya
Journal:  Biologics       Date:  2010-02-04

3.  Efficacy and Safety of Pergoveris in Assisted Reproductive Technology--ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment.

Authors:  P Humaidan; J Schertz; R Fischer
Journal:  BMJ Open       Date:  2015-07-03       Impact factor: 2.692

Review 4.  Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech.

Authors:  Rogério de Barros F Leão; Sandro C Esteves
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

5.  Results from adding recombinant LH for assisted reproductive technology treatment: A randomized control trial.

Authors:  Mohammad-Hossein Razi; Fereshteh Mohseni; Razieh Dehghani Firouzabadi; Sima Janati; Nahid Yari; Sahabeh Etebary
Journal:  Iran J Reprod Med       Date:  2014-02

6.  Effect of recombinant LH supplementation timing on clinical pregnancy outcome in long-acting GnRHa downregulated cycles.

Authors:  Chenyang Huang; Xiaoyue Shen; Jie Mei; Yanxin Sun; Haixiang Sun; Jun Xing
Journal:  BMC Pregnancy Childbirth       Date:  2022-08-09       Impact factor: 3.105

7.  Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study.

Authors:  José G Franco; Ricardo L R Baruffi; João Batista A Oliveira; Ana L Mauri; Claudia G Petersen; Paula Contart; Valeria Felipe
Journal:  Reprod Biol Endocrinol       Date:  2009-06-04       Impact factor: 5.211

Review 8.  Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.

Authors:  Philippe Lehert; Efstratios M Kolibianakis; Christos A Venetis; Joan Schertz; Helen Saunders; Pablo Arriagada; Samuel Copt; Basil Tarlatzis
Journal:  Reprod Biol Endocrinol       Date:  2014-02-20       Impact factor: 5.211

9.  Commentary: Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A Meta-analysis.

Authors:  Johnny S Younis
Journal:  Front Endocrinol (Lausanne)       Date:  2017-10-05       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.